ARDSLEY, N.Y. -- (BUSINESS WIRE) -- Acorda Therapeutics, Inc. (Nasdaq:ACOR) today joins people with epilepsy, advocacy organizations and healthcare professionals in recognizing Purple Day®. On March 26th people in countries around the world are invited to wear purple and host events in support of epilepsy awareness. Purple Day® was founded in 2008 by nine-year-old Cassidy Megan of Nova Scotia, and launched internationally in 2009. The Epilepsy Association of Nova Scotia and the Anita Kaufmann Foundation in the United States are the global partners for the Purple Day campaign®. One in 26 Americans will develop epilepsy during their lifetime.1
2014 National Walk for Epilepsy, Washington, DC, Sunday, March 22, 2014: I Walk Because(TM), part of the Acorda Community Outreach program, gives people a chance to tell their stories by decorating and personalizing t-shirts. (Photo: Business Wire)
Acorda also expressed support for the epilepsy community at the 2014 National Walk for Epilepsy in Washington, DC this past Sunday, March 22. In addition to bringing a walk team, this marked the first time Acorda brought its I Walk Because™ booth to an epilepsy event. I Walk Because, part of the Acorda Community Outreach program, is how Acorda exhibits its passion and dedication to the patient communities it serves. Staffed by employees of Acorda, the booth gives people a chance to tell their stories by decorating and personalizing t-shirts. The National Walk for Epilepsy, run by the Epilepsy Foundation of America, brings together a community of people dedicated to ending seizures and supporting people living with epilepsy.
Further highlighting Acorda’s commitment to the epilepsy community, the Company launched Clusterseizures.com – a website dedicated to providing information to healthcare professionals in an effort to help them serve some of their most vulnerable patients.
Epilepsy and Cluster Seizures
Epilepsy is a neurological condition that produces seizures affecting a variety of mental and physical functions. Seizures are symptoms of abnormal brain activity, and occur when a brief, strong surge of electrical activity affects part or all of the brain.
Of the approximately 2.3 million people in the United States with epilepsy2, it is estimated that about 175,000 experience cluster seizures. Cluster seizures, also known as acute repetitive seizures, are characterized by recognizable, recurring episodes of seizure clusters.
About Acorda Therapeutics
Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological conditions.
Acorda markets three FDA-approved therapies including: AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, a treatment to improve walking in patients with multiple sclerosis (MS); ZANAFLEX CAPSULES® (tizanidine hydrochloride) and Zanaflex tablets, a short-acting drug for the management of spasticity; and QUTENZA® (capsaicin) 8% Patch, for the management of neuropathic pain associated with postherpetic neuralgia. AMPYRA is marketed outside the United States as FAMPYRA® (prolonged-release fampridine tablets) by Biogen Idec under a licensing agreement from Acorda.
Acorda has one of the leading pipelines in the industry of novel neurological therapies. The Company is currently developing six clinical-stage therapies and one preclinical stage therapy that address a range of disorders including post-stroke deficits, epilepsy, cerebral palsy, stroke, peripheral nerve damage, spinal cord injury, neuropathic pain, and heart failure. For more information, please visit the Company’s website at: www.acorda.com.
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including our ability to successfully market and sell Ampyra in the U.S.; third party payers (including governmental agencies) may not reimburse for the use of Ampyra or our other products at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; the risk of unfavorable results from future studies of Ampyra or from our other research and development programs, including Plumiaz (our trade name for Diazepam Nasal Spray), or any other acquired or in-licensed programs; we may not be able to complete development of, obtain regulatory approval for, or successfully market Diazepam Nasal Spray or other products under development; the occurrence of adverse safety events with our products; delays in obtaining or failure to obtain regulatory approval of or to successfully market Fampyra outside of the U.S. and our dependence on our collaboration partner Biogen Idec in connection therewith; competition, including the impact of generic competition on Zanaflex Capsules revenues; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products; failure to comply with regulatory requirements could result in adverse action by regulatory agencies; and the ability to obtain additional financing to support our operations. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities & Exchange Commission. Acorda may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this release are made only as of the date hereof, and Acorda disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this release.
Hesdorffer, DC, PhD, et al. (2011) Estimating risk for developing epilepsy. Neurology. vol. 76 no. 1 23-27. doi: 10.1212/WNL.0b013e318204a36a
National Institute of Neurological Disorders and Stroke 2012; http://www.ninds.nih.gov/disorders/epilepsy/epilepsy_research.htm; accessed 23 April 2012